Dr. Frank Eder, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York Downstate Medical Center (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: State University of New York Downstate Medical Center
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NY license 197948
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- United Health Services Hospitals, Inc Binghamton, NY
- Our Lady of Lourdes Memorial Hospital, Inc Binghamton, NY
Medical groups
- United Health Services Hospitals, Inc. (477 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 712
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 229 | 123 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 148 | 42 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 66 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 28 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 26 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 22 |
| Hospital discharge day management, 30 minutes or less | 20 | 18 |
| Hospital discharge day management, more than 30 minutes | 14 | 14 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 90 payments worth $2,064 in total to this clinician.
| Food and Beverage | $2,064 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 37 industry-funded studies in 2025, from 16 companies. The companies reported $2,867,748 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Sanofi Pasteur Inc. · Active, not recruiting · NCT06838000 - A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
AstraZeneca Pharmaceuticals LP - Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
Sanofi Pasteur Inc. · Completed · NCT06237296 - A phase 3 multicenter placebocontrolled randomized observerblinded trial to evaluate the efficacy safety tolerability immunogenicity and lot consistency of a 6VALENT ospabased lyme disease vaccine in healthy participa…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.